Apellis Pharmaceuticals (NASDAQ:APLS) has been assigned a consensus broker rating score of 1.50 (Buy) from the four brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and three have assigned a strong buy recommendation to the company. Apellis Pharmaceuticals’ rating score has declined by 50% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Brokers have set a 1-year consensus price objective of $35.25 for the company and are anticipating that the company will post ($0.27) EPS for the current quarter, according to Zacks. Zacks has also assigned Apellis Pharmaceuticals an industry rank of 178 out of 265 based on the ratings given to its competitors.
APLS has been the subject of several research analyst reports. B. Riley initiated coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, February 8th. They issued a “buy” rating and a $27.00 price objective for the company. JPMorgan Chase upped their price objective on shares of Apellis Pharmaceuticals from $31.00 to $35.00 and gave the company an “overweight” rating in a research note on Friday, March 23rd. Finally, Zacks Investment Research upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a research note on Tuesday, March 27th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in APLS. Jennison Associates LLC acquired a new position in Apellis Pharmaceuticals in the fourth quarter valued at $13,170,000. Quantitative Systematic Strategies LLC acquired a new position in Apellis Pharmaceuticals in the fourth quarter valued at $317,000. NF Trinity Capital Hong Kong Ltd acquired a new position in Apellis Pharmaceuticals in the fourth quarter valued at $7,750,000. Candriam Luxembourg S.C.A. acquired a new position in Apellis Pharmaceuticals in the fourth quarter valued at $2,539,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Apellis Pharmaceuticals in the fourth quarter valued at about $186,000. Institutional investors own 31.26% of the company’s stock.
Shares of APLS stock opened at $26.73 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 27.79 and a quick ratio of 27.79. The firm has a market cap of $1,346.46 and a P/E ratio of -7.28. Apellis Pharmaceuticals has a 12 month low of $12.45 and a 12 month high of $29.34.
Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Monday, March 19th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33). sell-side analysts anticipate that Apellis Pharmaceuticals will post -1.16 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Apellis Pharmaceuticals (APLS) Given Consensus Rating of “Buy” by Analysts” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/04/16/apellis-pharmaceuticals-apls-given-consensus-rating-of-buy-by-analysts.html.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.